Introduction: Nitrosamine root cause investigation for injectable drugs is a critical analytical and pharmaceutical-development activity whenever a nitrosamine impurity is […]
Introduction: Therapeutic peptide characterization for NDA and ANDA submissions sits at the intersection of analytical chemistry and regulatory strategy, and
Introduction: The right CDMO capabilities for generic injectable ANDA development should cover the entire product lifecycle — from formulation and
CDMO Capabilities Checklist for Complex Generic Injectable ANDA Projects Read More »
Introduction: Extractable & Leachable Testing for Clinical to Commercial Scale-Up is essential because changes introduced during manufacturing scale-up can alter
Introduction: Peptide technology transfer to a CDMO is more than transferring a manufacturing recipe — it requires transfer of product,
Introduction Executing Generic Ophthalmic Suspension ANDA Development requires a comprehensive technical strategy that integrates qualitative and quantitative formulation sameness (Q1/Q2),
Introduction Impurity Control Strategies Under ICH Q3A and Q3B establish a risk-based regulatory framework used by global health authorities to
Impurity Control Strategies Under ICH Q3A and Q3B for Generic Drug ANDA Submissions Read More »
Introduction Outsourcing your first generic drug project to a CDMO requires a structured technical transition that covers candidate characterization, technology
Outsourcing Your First Generic Drug Project to a CDMO: A Step-by-Step Sponsor Guide Read More »
Introduction Container Closure System Selection and Qualification for generic parenteral drug products involves the systematic evaluation and validation of primary
Introduction End-to-End ANDA Analytical Package Development for a complex generic suspension requires an integrated analytical framework that connects qualitative (Q1)
